Drug profile · INN
dupixent
dupixent is a interleukin-4 receptor subunit alpha antagonist.
Drug details — dupixent
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.70
Quick answer
dupixent is a interleukin-4 receptor subunit alpha antagonist.
Key facts
Mechanism of action
Interleukin-4 receptor subunit alpha antagonist
Primary target: Interleukin-4 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Recent coverage
Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
This plan frames a Sanofi pipeline pdf-style news brief around 2026 clinical catalysts, with Dupixent as the anchor asset and Lantus as a mature revenue base. It also clarifies the Sanofi Pasteur MSD joint venture structure and why the pipeline matters for analysts and BD teams.
FDA approves Dupixent for COPD with eosinophilic phenotype
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Related & competitor drugs
Frequently asked questions
What is dupixent?
dupixent is a interleukin-4 receptor subunit alpha antagonist.